Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00223691 · ClinicalTrials.gov registry record · Phase 1
Treatment of Orthostatic Hypotension in Autonomic Failure
A Phase 1 study, sponsored by Vanderbilt University.
- Completed
- Registry status
- Phase 1
- Development phase
- 389
- Enrollment target
NCT00223691 is a Phase 1 study that has completed, run by Vanderbilt University. The registered enrollment target is 389 participants.
The verdict
NCT00223691, a Phase 1 study, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 389 participants
- Enrollment target
Study Summary
The autonomic nervous system serves multiple regulatory functions in the body, including the regulation of blood pressure and heart rate, gut motility, sweating and sexual function. There are several diseases characterized by abnormal function of the autonomic nervous system. Medications can also alter autonomic function. Impairment of the autonomic nervous system by diseases or drugs may lead to several symptoms, including blood pressure problems (e.g., high blood pressure lying down and low blood pressure on standing), sweating abnormalities, constipation or diarrhea and sexual dysfunction. Because treatment options for these patients are limited. We propose to study patients autonomic failure and low blood pressure upon standing and determine the cause of their disease by history and examination and their response to autonomic testing which have already been standardized in our laboratory. Based on their possible cause, we will tests different medications that may alleviate their symptoms.
Interventions
- DRUG Pyridostigmine Bromide
- DRUG Atomoxetine
- DRUG Yohimbine
- DRUG Midodrine HCl
- DRUG Acarbose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 389 participants |
| Start Date | 2002-03 |
| Est. Completion | 2017-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00223691
The ClinicalTrials.gov registry entry for NCT00223691 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 389 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Pyridostigmine Bromide is the first listed.
NCT00223691 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00223691 about?
NCT00223691 is a clinical study titled "Treatment of Orthostatic Hypotension in Autonomic Failure". The autonomic nervous system serves multiple regulatory functions in the body, including the regulation of blood pressure and heart rate, gut motility, sweating and sexual function. There are several diseases characterized by abnormal function of the autonomic nervous system. Medications can also al...
What is the current status of trial NCT00223691?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 389 participants. The study started on 2002-03. Estimated completion is 2017-01.
What interventions are being tested in trial NCT00223691?
The interventions under investigation include: Pyridostigmine Bromide (DRUG), Atomoxetine (DRUG), Yohimbine (DRUG), Midodrine HCl (DRUG), Acarbose (DRUG).
Who is sponsoring clinical trial NCT00223691?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.